中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.022 seconds)

    Dolastatin 15 derivatives
    1.
    发明专利
    Dolastatin 15 derivatives 未知

    公开(公告)号：AU750120B2

    公开(公告)日：2002-07-11

    申请号：AU8475898

    申请日：1998-07-07

    Applicant: BASF AG ,  BASF BIORES CORP

    Inventor： JANSSEN BERND ,  BARLOZZARI TERESA ,  HAUPT ANDREAS ,  ZIERKE THOMAS ,  KLING ANDREAS

    IPC: A61K38/00 ,  A61K38/08 ,  A61P35/00 ,  C07K7/06 ,  C12P19/34

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L  (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

    5.
    发明专利
    未知

    公开(公告)号：NO20010046L

    公开(公告)日：2001-03-02

    申请号：NO20010046

    申请日：2001-01-04

    Applicant: BASF BIORES CORP

    Inventor： RITTER KURT ,  JANSSEN BERND ,  HAUPT ANDREAS ,  KLING ANDREAS ,  BARLOZZARI TERESA ,  AMBERG WILHELM

    IPC: A61K38/00 ,  A61K35/56 ,  A61P35/00 ,  C07K5/103 ,  C07K5/117 ,  C07K7/02 ,  C07K7/06 ,  A61K38/08

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA-B-D-E-F-G(I)and acid salts thereof, wherein A, D, and E are alpha -amino acid residues, B is an alpha -amino acid residue or an alpha -hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a beta -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

    6.
    发明专利
    未知

    公开(公告)号：NO20010046D0

    公开(公告)日：2001-01-04

    申请号：NO20010046

    申请日：2001-01-04

    Applicant: BASF AG ,  BASF BIORES CORP

    Inventor： RITTER KURT ,  JANSSEN BERND ,  HAUPT ANDREAS ,  KLING ANDREAS ,  BARLOZZARI TERESA ,  AMBERG WILHELM

    IPC: A61K38/00 ,  A61K35/56 ,  A61P35/00 ,  C07K5/103 ,  C07K5/117 ,  C07K7/02 ,  C07K

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA-B-D-E-F-G(I)and acid salts thereof, wherein A, D, and E are alpha -amino acid residues, B is an alpha -amino acid residue or an alpha -hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a beta -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Patent Agency Ranking